Long-Term Insulin Independence and Improvement in Insulin Secretion After Supplemental Islet Infusion Under Exenatide and Etanercept | Zendy

Raquel N. Faradji | Zendy; Thipaporn Tharavanij | Zendy; Shari Messinger | Zendy; Tatiana Froud | Zendy; Antonello Pileggi | Zendy; Kathy Monroy | Zendy; Davide Mineo | Zendy; David A. Baidal | Zendy; Pablo Cure | Zendy; Gaston Ponte | Zendy; Armando J. Mendez | Zendy; Gennaro Selvaggi | Zendy; Camillo Ricordi | Zendy; Rodolfo Alejandro | Zendy

Open Access

Long-Term Insulin Independence and Improvement in Insulin Secretion After Supplemental Islet Infusion Under Exenatide and Etanercept

Author(s) -

Raquel N. Faradji,

Thipaporn Tharavanij,

Shari Messinger,

Tatiana Froud,

Antonello Pileggi,

Kathy Monroy,

Davide Mineo,

David A. Baidal,

Pablo Cure,

Gaston Ponte,

Armando J. Mendez,

Gennaro Selvaggi,

Camillo Ricordi,

Rodolfo Alejandro

Publication year - 2008

Publication title -

transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.45

H-Index - 204

eISSN - 1534-6080

pISSN - 0041-1337

DOI - 10.1097/tp.0b013e31818fe448

Subject(s) - medicine , islet , exenatide , daclizumab , insulin , etanercept , endocrinology , gastroenterology , transplantation , type 2 diabetes , diabetes mellitus , rheumatoid arthritis , tacrolimus

Progressive graft dysfunction (GDF) and loss of insulin independence (II) have been invariably observed in islet transplant recipients under the "Edmonton protocol." To reestablish II, we performed supplemental islet infusions (SI) in recipients of allogeneic islet transplant alone, displaying GDF. To improve the engraftment and long-term graft function of SI, exenatide (EXN) and etanercept treatment at islet infusion, and long-term EXN treatment were tested in a non-randomized pilot clinical trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research